17 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
future approved products;
injury to our reputation;
withdrawal of clinical trial participants;
termination of clinical trial sites or entire trial … or injury, and any related liability, resulting from medical or hazardous materials.
Material modifications in methods of product candidate manufacturing
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
claims may result in:
decreased demand for any future approved products;
injury to our reputation;
withdrawal of clinical trial participants … eliminate the risk of contamination or injury, and any related liability, resulting from medical or hazardous materials.
Material modifications
8-K
EX-10.1
obut0f5 qkeoq
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
8z2hk4ypo 2o
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
gpw8sywcgh
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
83ekov8t0jnuymh57mu
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am
424B5
fi9jz5 8w
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
2rshi83a0
8 Nov 22
Quarterly report
4:09pm
424B5
vewxfrffubymts m9p3w
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
tgi1w
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
424B5
hx06d
13 Oct 22
Prospectus supplement for primary offering
4:56pm
- Prev
- 1
- Next